BiotechTube

Octreotide + Placebo + Everolimus

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Carcinoid Tumor

Conditions

Carcinoid Tumor, Malignant Carcinoid Syndrome

Trial Timeline

Dec 1, 2006 → Jun 1, 2013

NCT ID
NCT00412061

About Octreotide + Placebo + Everolimus

Octreotide + Placebo + Everolimus is a phase 3 stage product being developed by Novartis for Carcinoid Tumor. The current trial status is completed. This product is registered under clinical trial identifier NCT00412061. Target conditions include Carcinoid Tumor, Malignant Carcinoid Syndrome.

What happened to similar drugs?

1 of 8 similar drugs in Carcinoid Tumor were approved

Approved (1) Terminated (1) Active (6)
✅lanreotide (Autogel formulation)IpsenApproved
🔄Pasireotide + OctreotideNovartisPhase 3
❌lanreotide Autogel (somatostatin analogue) + Sandostatin long acting release (LAR) Depot (somatostatin analogue)IpsenPhase 3
🔄Lanreotide + PlaceboIpsenPhase 3
🔄Paltusotine + PlaceboCrinetics PharmaceuticalsPhase 3
🔄Telotristat etiprate + Placebo-matching telotristat etiprateLexicon PharmaceuticalsPhase 3
🔄Telotristat etiprateLexicon PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00412061Phase 3Completed

Competing Products

20 competing products in Carcinoid Tumor

See all competitors
ProductCompanyStageHype Score
Ramucirumab + Somatostatin AnalogEli LillyPhase 2
35
PasireotideNovartisPhase 1
29
Pasireotide + OctreotideNovartisPhase 3
40
Pasireotide (SOM230)NovartisPhase 2
35
LutatheraNovartisPhase 2
27
EPO906 epothilone BNovartisPhase 2
35
PanitumumabAmgenPhase 2
27
AxitinibPfizerPhase 2
35
Lanreotide + Placebo (for sunitinib) + SunitinibPfizerPhase 2
31
Nivolumab + CabozantinibBristol Myers SquibbPhase 2
35
bevacizumab + 5-fluorouracil + leucovorin + oxaliplatinSanofiPhase 2/3
30
lanreotide Autogel (somatostatin analogue) + Sandostatin long acting release (LAR) Depot (somatostatin analogue)IpsenPhase 3
29
lanreotide (Autogel formulation)IpsenApproved
40
Lanreotide + PlaceboIpsenPhase 3
37
BIM 23A760IpsenPhase 2
24
Randomized: 40 mg Paltusotine + Randomized: 80 mg PaltusotineCrinetics PharmaceuticalsPhase 2
32
Paltusotine + PlaceboCrinetics PharmaceuticalsPhase 3
44
Telotristat etiprate + Placebo-matching telotristat etiprateLexicon PharmaceuticalsPhase 3
34
Telotristat etiprateLexicon PharmaceuticalsPhase 3
34
500 mg [14C]-LX1606Lexicon PharmaceuticalsPhase 1
23